Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
14 Dezembro 2022 - 07:09PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of December 2022
001-36345
(Commission
File Number)
GALMED
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
16
Tiomkin St.
Tel
Aviv 6578317, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form
20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation
S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation
S-T Rule 101(b)(7): ____
On December
14, 2022, Galmed Pharmaceuticals Ltd. issued a press release entitled “Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt
of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement.”
A copy
of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
This 6-K and the press release
attached as Exhibit 99.1 to this Form 6-K are incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration
No. 333-206292 and 333-227441) and the Company’s Registration Statement on Form F-3 (Registration No. 333-254766).
EXHIBIT
INDEX
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Galmed Pharmaceuticals Ltd. |
|
|
Date: December 14 2022 |
By: |
/s/
Allen Baharaff |
|
|
Allen Baharaff |
|
|
President and Chief Executive Officer |
Galmed Pharmaceuticals (NASDAQ:GLMD)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Galmed Pharmaceuticals (NASDAQ:GLMD)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024